Post–Coronavirus Disease 2019 Pulmonary Fibrosis: Wait or Needs Intervention

다국어 초록 (Multilingual Abstract)

Coronavirus disease 2019 (COVID-19) has become a major health burden worldwide, with over 450 million confirmed cases and 6 million deaths. Although the acute phase of COVID-19 management has been established, there is still a long way to go to evaluate the long-term clinical course or manage complications due to the relatively short outbreak of the virus. Pulmonary fibrosis is one of the most common respiratory complications associated with COVID-19. Scarring throughout the lungs after viral or bacterial pulmonary infection have been commonly observed, but the prevalence of post– COVID-19 pulmonary fibrosis is rapidly increasing. However, there is limited information available about post–COVID-19 pulmonary fibrosis, and there is also a lack of consensus on what condition should be defined as post–COVID-19 pulmonary fibrosis. During a relatively short follow-up period of approximately 1 year, lesions considered related to pulmonary fibrosis often showed gradual improvement; therefore, it is questionable at what time point fibrosis should be evaluated. In this review, we investigated the epidemiology, risk factors, pathogenesis, and management of post–COVID-19 pulmonary fibrosis.

참고문헌 (Reference)

1 Myers JL, "Ultrastructural evidence of alveolar epithelial injury in idiopathic bronchiolitis obliterans-organizing pneumonia" 132 : 102-109, 1988

2 Piguet PF, "Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis" 170 : 655-663, 1989

3 Gupta S, "Tocilizumab in patients hospitalized with COVID-19 pneumonia : systematic review and meta-analysis of randomized controlled trials" 70 : 55-60, 2022

4 Liang Limei ; Yang Bohan ; Jiang Nanchuan ; Fu Wei ; He Xinliang ; Zhou Yaya ; Ma Wan-Li ; Wang Xiaorong, "Three-Month Follow-Up Study of Survivors of Coronavirus Disease 2019 after Discharge" 대한의학회 35 (35): 1-15, 2020

5 "The study of the use of nintedanib in slowing lung disease in patients with fibrotic or non-fibrotic interstitial lung disease related to COVID-19 (ENDCOV-I)" U.S. National Library of Medicine

6 Huang W, "The potential indicators for pulmonary fibrosis in survivors of severe COVID-19" 82 : e5-e7, 2021

7 Fernandez IE, "The impact of TGF-beta on lung fibrosis : from targeting to biomarkers" 9 : 111-116, 2012

8 Zou JN, "The characteristics and evolution of pulmonary fibrosis in COVID-19 patients as assessed by AI-assisted chest HRCT" 16 : e0248957-, 2021

9 "The MONACO cell therapy study: monocytes as an anti-fibrotic treatment after COVID-19 (MONACO)" U.S. National Library of Medicine

10 Ragab D, "The COVID-19 cytokine storm : what we know so far" 11 : 1446-, 2020

11 Bilgili H, "Telomere abnormalities in the pathobiology of idiopathic pulmonary fibrosis" 8 : 1232-, 2019

12 Yue X, "TGF-beta : titan of lung fibrogenesis" 6 : 2010

13 Tenforde MW, "Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network -United States, March-June 2020" 69 : 993-998, 2020

14 Peiro C, "Substituting angiotensin-(1-7)to prevent lung damage in SARS-CoV-2 infection?" 141 : 1665-1666, 2020

15 Chopra V, "Sixty-day outcomes among patients hospitalized with COVID-19" 174 : 576-578, 2021

16 Han X, "Sixmonth follow-up chest CT findings after severe COVID-19pneumonia" 299 : E177-86, 2021

17 "Safety and effectiveness of EV-Pure + WJ-Pure treatment on pulmonary fibrosis secondary to COVID-19" U.S. National Library of Medicine

18 Xu J, "SARSCoV-2 induces transcriptional signatures in human lung epithelial cells that promote lung fibrosis" 21 : 182-, 2020

19 Liu K, "Respiratory rehabilitation in elderly patients with COVID-19 : a randomized controlled study" 39 : 101166-, 2020

20 Piguet PF, "Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosis" 344 : 245-247, 1990

21 Goodwin VA, "Rehabilitation to enable recovery from COVID-19 : a rapid systematic review" 111 : 4-22, 2021

22 Dowman L, "Pulmonary rehabilitation for interstitial lung disease" 6 : CD006322-, 2014

23 Guler SA, "Pulmonary function and radiological features 4 months after COVID-19 : first results from the national prospective observational Swiss COVID-19 lung study" 57 : 2003690-, 2021

24 Wilson MS, "Pulmonary fibrosis: pathogenesis, etiology and regulation" 2 : 103-121, 2009

25 Li X, "Pulmonary fibrosis and its related factors in discharged patients with new corona virus pneumonia : a cohort study" 22 : 203-, 2021

26 McGroder CF, "Pulmonary fibrosis 4months after COVID-19 is associated with severity of illness and blood leucocyte telomere length" 76 : 1242-1245, 2021

27 Yu Minhua ; Liu Ying ; Xu Dan ; Zhang Rongguo ; Lan Lan ; Xu Haibo, "Prediction of the Development of Pulmonary Fibrosis Using Serial Thin-Section CT and Clinical Features in Patients Discharged after Treatment for COVID-19 Pneumonia" 대한영상의학회 21 (21): 746-755, 2020

28 Yasin R, "Predicting lung fibrosis in post-COVID-19 patients after discharge with follow-up chest CT findings" 52 : 118-, 2021

29 Caruso D, "Post-acute sequelae of COVID-19pneumonia : six-month chest CT follow-up" 301 : E396-405, 2021

30 Nalbandian A, "Post-acute COVID-19 syndrome" 27 : 601-615, 2021

31 Nabahati M, "Post-COVID-19 pulmonary fibrosis and its predictive factors : a prospective study" 52 : 248-, 2021

32 "Pirfenidone vs. nintedanib for fibrotic Llung disease after coronavirus disease-19 pneumonia (PINCER)" U.S. National Library of Medicine

33 "Pirfenidone compared to placebo in post-COVID19pulmonary fibrosis COVID-19 (FIBRO-COVID)" U.S. National Library of Medicine

34 Ruwanpura SM, "Pirfenidone : molecular mechanisms and potential clinical applications in lung disease" 62 : 413-422, 2020

35 "Pilot study to assess efficacy and safety of treamid in the rehabilitation of patients after COVID-19 pneumonia" U.S. National Library of Medicine

36 CarfiA, "Persistent symptoms in patients after acute COVID-19" 324 : 603-605, 2020

37 Myall KJ, "Persistent post-COVID-19 interstitial lung disease : an observational study of corticosteroid treatment" 18 : 799-806, 2021

38 Martin-Villares C, "Outcome of 1890 tracheostomies for critical COVID-19 patients : a national cohort study in Spain" 278 : 1605-1612, 2021

39 Ogata H, "Nintedanib treatment for pulmonary fibrosis after coronavirus disease 2019" 9 : e00744-, 2021

40 "Nintedanib for the treatment of SARS-Cov-2 induced pulmonary fibrosis" U.S. National Library of Medicine

41 Strieter RM, "New mechanisms of pulmonary fibrosis" 136 : 1364-1370, 2009

42 Kis K, "Myofibroblast differentiation and survival in fibrotic disease" 13 : e27-, 2011

43 Wollin L, "Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis" 45 : 1434-1445, 2015

44 Turrens JF, "Mitochondrial formation of reactive oxygen species" 552 : 335-344, 2003

45 Bueno M, "Mitochondria dysfunction and metabolic reprogramming as drivers of idiopathic pulmonary fibrosis" 33 : 101509-, 2020

46 "Mineralocorticoid receptor antagonist and pulmonary fibrosis in COVID-19" U.S. National Library of Medicine

47 Bharat A, "Lung transplantation for patients with severe COVID-19" 12 : eabe4282-, 2020

48 Chen JY, "Lung transplantation as therapeutic option in acute respiratory distress syndrome for coronavirus disease 2019-related pulmonary fibrosis" 133 : 1390-1396, 2019

49 Bazdyrev E, "Lung fibrosis after COVID-19: treatment prospects" 14 : 807-, 2021

50 Zhang P, "Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome : a 15-year follow-up from a prospective cohort study" 8 : 8-, 2020

51 "LYT-100 in post-acute COVID-19 respiratory disease" U.S. National Library of Medicine

52 Nathani N, "Kerbs von Lungren 6 antigen is a marker of alveolar inflammation but not of infection in patients with acute respiratory distress syndrome" 12 : R12-, 2008

53 Moodley YP, "Inverse effects of interleukin-6 on apoptosis of fibroblasts from pulmonary fibrosis and normal lungs" 29 : 490-498, 2003

54 "Intramuscular effect of polymerized type I collagen on the cytokine storm in COVID-19 patients" U.S. National Library of Medicine

55 Gulati A, "Interstitial lung abnormalities and pulmonary fibrosis in COVID-19 patients : a short-term follow-up case series" 77 : 180-186, 2021

56 Huang Y, "Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase" 21 : 163-, 2020

57 Das KC, "Hyperoxia decreases glycolytic capacity, glycolytic reserve and oxidative phosphorylation in MLE-12cells and inhibits complex I and II function, but not complex IV in isolated mouse lung mitochondria" 8 : e73358-, 2013

58 van Gassel RJ, "High prevalence of pulmonary sequelae at 3 months after hospital discharge in mechanically ventilated survivors of COVID-19" 203 : 371-374, 2021

59 Writing Committee for the COMEBAC Study Group, "Fourmonth clinical status of a cohort of patients after hospitalization for COVID-19" 325 : 1525-1534, 2021

60 Hansell DM, "Fleischner Society : glossary of terms for thoracic imaging" 246 : 697-722, 2008

61 Marvisi M, "First report on clinical and radiological features of COVID-19 pneumonitis in a Caucasian population : factors predicting fibrotic evolution" 99 : 485-488, 2020

62 Han X, "Fibrotic interstitial lung abnormalities at 1-year follow-up CT after severe COVID-19" 301 : E438-40, 2021

63 Piguet PF, "Expression and localization of tumor necrosis factor-alpha and its mRNA in idiopathic pulmonary fibrosis" 143 : 651-655, 1993

64 Shieh JM, "Elevation of IL-6 and IL-33 levels in serum associated with lung fibrosis and skeletal muscle wasting in a bleomycin-induced lung injury mouse model" 2019 : 7947596-, 2019

65 Richeldi L, "Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis" 370 : 2071-2082, 2014

66 Umemura Y, "Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19 : an interventional study" 108 : 454-460, 2021

67 Marwah V, "Early experience of nintedanib in COVID-19 ARDS-related pulmonary fibrosis : a case series" 89 : 589-596, 2021

68 Gao Y, "Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19" 92 : 791-796, 2020

69 Zhang H, "Diagnostic and prognostic predictive values of circulating KL-6 for interstitial lung disease: a PRISMA-compliant systematic review and meta-analysis" 99 : e19493-, 2020

70 Recovery Collaborative Group, "Dexamethasone in hospitalized patients with COVID-19" 384 : 693-704, 2021

71 Peng DH, "Correlation of Krebs von den Lungen-6 and fibronectin with pulmonary fibrosis in coronavirus disease 2019" 517 : 48-53, 2021

72 Da BL, "Coronavirus disease 2019hangover : a rising tide of alcohol use disorder and alcohol-associated liver disease" 72 : 1102-1108, 2020

73 Aul DR, "Complications after discharge with COVID-19 infection and risk factors associated with development of post-COVID pulmonary fibrosis" 188 : 106602-, 2021

74 "Colchicine and post-COVID-19 pulmonary fibrosis" U.S. National Library of Medicine

75 Ruan Q, "Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China" 46 : 846-848, 2020

76 Huang C, "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China" 395 : 497-506, 2020

77 Farghaly S, "Clinical characteristics and outcomes of post-COVID-19 pulmonary fibrosis: a case-control study" 101 : e28639-, 2022

78 Chen G, "Clinical and immunological features of severe and moderate coronavirus disease 2019" 130 : 2620-2629, 2020

79 Pan F, "Chest CT patterns from diagnosis to 1 year of follow-up in patients with COVID-19" 302 : 709-719, 2022

80 Cocconcelli E, "Characteristics and prognostic factors of pulmonary fibrosis after COVID-19 pneumonia" 8 : 823600-, 2021

81 Sonnweber T, "Cardiopulmonary recovery after COVID-19 : an observational prospective multicentre trial" 57 : 2003481-, 2021

82 Beyerstedt S, "COVID-19 : angiotensin-converting enzyme 2(ACE2)expression and tissue susceptibility to SARS-CoV-2 infection" 40 : 905-919, 2021

83 Le TT, "Blockade of IL-6 Trans signaling attenuates pulmonary fibrosis" 193 : 3755-3768, 2014

84 "Assessing the efficacy of sirolimus in patients with COVID-19 pneumonia for prevention of post-COVID fibrosis" U.S. National Library of Medicine

85 Liu W, "Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease" 133 : 1032-1038, 2020

86 Chen L, "Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia" 43 : 203-208, 2020

87 Zhang F, "A trial of pirfenidone in hospitalized adult patients with severe coronavirus disease 2019" 135 : 368-370, 2021

88 "A study to evaluate the efficacy and safety of pirfenidone with novel coronavirus infection" U.S. National Library of Medicine

89 King TE Jr, "A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis" 370 : 2083-2092, 2014

90 Huang L, "1-year outcomes in hospital survivors with COVID-19 : a longitudinal cohort study" 398 : 747-758, 2021